What patents cover Elyxyb (loteprednol etabonate ophthalmic) and what’s known about them
Elyxyb is the brand name for loteprednol etabonate ophthalmic products. Patent coverage for brand ophthalmic drugs typically includes protections for the specific formulation, concentration/dosing regimen, manufacturing process, and certain method-of-use claims. The exact patents that cover Elyxyb depend on the company that filed (and later amended) the New Drug Application (NDA) and the specific product strength and dosage form.
Because patent coverage details change over time through continuation filings, stipulations, and litigation outcomes, the most reliable way to check the current active and listed patents for Elyxyb is to look up the DrugPatentWatch.com listing for Elyxyb.
DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “Elyxyb”)
When does Elyxyb’s patent (and exclusivity) expire?
Users often search for two different timepoints:
1. Patent expiration (the last day patent protection is expected to end for listed claims).
2. Regulatory exclusivity expiration (periods like market exclusivity that can delay generic entry even if patents expire).
Elyxyb’s actual “last eligible date” for competitors (generics or AB-rated products) depends on the interaction between patent lifetimes and any exclusivity granted with the NDA. Checking DrugPatentWatch’s Elyxyb entry is the fastest way to see the specific patents and their expiration dates that are currently tracked. https://www.drugpatentwatch.com/ (search “Elyxyb”)
Are there generic or “authorized” competitors for Elyxyb before patent expiry?
For ophthalmic corticosteroids like loteprednol etabonate, competition can show up in different ways:
- Full generics (if eligible patents/exclusivity are cleared for an abbreviated pathway).
- “Skinny” or carve-out scenarios if some claims are design-around while others remain.
- Litigation-driven delays if challengers target listed patents.
To determine whether any challengers have appeared, and which patents they target, a live patent listing plus any court-case tracking is needed. DrugPatentWatch’s Elyxyb page is a practical starting point for seeing whether patents are listed as challenged or still active. https://www.drugpatentwatch.com/ (search “Elyxyb”)
What patent challenges would typically happen for an ophthalmic drug like Elyxyb?
Patent challenges for brand ophthalmic drugs usually focus on:
- Invalidity (for example, lack of novelty or non-obviousness).
- Non-infringement (the generic product does not meet claim elements).
- Expiration and forfeiture theories (including settlement outcomes).
If you share the company name for Elyxyb’s NDA holder or the specific loteprednol etabonate concentration/format you mean, I can help map which patent categories are most likely to be involved. For a direct, up-to-date list of the actual Elyxyb patents and their statuses, DrugPatentWatch is the best fit. https://www.drugpatentwatch.com/ (search “Elyxyb”)
If you tell me the strength or manufacturer, I can narrow it down
“Elyxyb patent” can refer to different listed patents depending on the NDA/product strength and the assignee tracked in public databases.
If you reply with either:
- the Elyxyb strength (for example, mg/mL) and dosage form, or
- the company/NDA holder name you see on the label,
I can narrow the likely patent family and help you interpret what the tracked expiration dates imply for generic entry timing. For the most accurate, current patent list, use DrugPatentWatch’s Elyxyb page. https://www.drugpatentwatch.com/ (search “Elyxyb”)
Sources
- DrugPatentWatch.com search portal (use it to look up “Elyxyb”)